NCT06448572View on ClinicalTrials.gov

EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

21

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

October 1, 2028

Study Completion Date

October 1, 2028

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

EXL01

1 capsule / day

Trial Locations (1)

59000

RECRUITING

CHU Lille, Lille

Sponsors

Collaborators (1)

Exeliom Biosciences

All Listed Sponsors

collaborator

Exeliom Biosciences

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT06448572 - EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy. | Biotech Hunter | Biotech Hunter